Ocular Therapeutix reported a phase 3 win that it believes can validate its attempts to challenge Regeneron’s entrenched ...
Investors were looking for a greater difference between Ocular’s experimental medicine and a low-dose version of Eylea, ...
In the recreation room at Eskaton Village in Carmichael, Bonnie Dale, one of the residents, is trying on a virtual reality ...
Ocular Therapeutix (OCUL) stock falls as the company posts late-stage trial data for Axpaxli, its experimental drug for Wet AMD. Read more here.
Ocular now plans to apply for FDA approval, but whether doctors and insurers will favor its new drug is an open question.
Ocular Therapeutix has released positive topline results from SOL-1, its phase 3 superiority trial of AXPAXLI for the ...
Rahul Tonk, MD, MBA attended Envision Summit 2026 to present on refractive surgery, dry eye, and ocular surface disease. In the CE Spotlight Symposium titled “Emerging Therapeutic Advancements in Dry ...
Grip strength correlates with working memory performance and prefrontal activation, highlighting its potential as a cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results